Onco Wiki / Regimen

Dabrafenib + trametinib (BRAF V600E+ NSCLC)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

ComponentsDRUG-DABRAFENIB DRUG-TRAMETINIB
IDREG-DABRAFENIB-TRAMETINIB-NSCLC
TypeRegimen
Statuspending_clinical_signoff
DiseasesNone declared
SourcesSRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025

Notes

BRF113928: ORR ~64% in 1L BRAF V600E+ NSCLC. Pyrexia management dominant clinical challenge.

Used By

Indication

Regimen